Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

https://doi.org/10.1016/j.jcf.2021.03.017Get rights and content
Under a Creative Commons license
open access

Highlights

  • We report 130 SARS-CoV-2 cases in people with CF (pwCF) to June 2020 across Europe.

  • Reported incidence was higher in pwCF versus the age-matched general population.

  • pwCF had more hospital and intensive care admissions than the general population.

  • Lung-transplanted pwCF had more severe illness and needed more care.

  • SARS-CoV-2 can cause severe disease in pwCF justifying priority vaccination.

Abstract

Background

Viral infections can cause significant morbidity in cystic fibrosis (CF). The current Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic could therefore have a serious impact on the health of people with CF (pwCF).

Methods

We used the 38-country European Cystic Fibrosis Society Patient Registry (ECFSPR) to collect case data about pwCF and SARS-CoV-2 infection.

Results

Up to 30 June 2020, 16 countries reported 130 SARS-CoV-2 cases in people with CF, yielding an incidence of 2.70/1000 pwCF. Incidence was higher in lung-transplanted patients (n=23) versus non-transplanted patients (n=107) (8.43 versus 2.36 cases/1000). Incidence was higher in pwCF versus the age-matched general population in the age groups <15, 15-24, and 25-49 years (p<0.001), with similar trends for pwCF with and without lung transplant. Compared to the general population, pwCF (regardless of transplantation status) had significantly higher rates of admission to hospital for all age groups with available data, and higher rates of intensive care, although not statistically significant.

Most pwCF recovered (96.2%), however 5 died, of whom 3 were lung transplant recipients. The case fatality rate for pwCF (3.85%, 95% CI: 1.26-8.75) was non-significantly lower than that of the general population (7.46%; p=0.133).

Conclusions

SARS-CoV-2 infection can result in severe illness and death for pwCF, even for younger patients and especially for lung transplant recipients. PwCF should continue to shield from infection and should be prioritized for vaccination.

Keywords

Cystic fibrosis
Covid-19
SARS-CoV-2
Europe
Incidence
Epidemiology

Cited by (0)

Contributed equally as first author

⁎⁎

Contributed equally as last author